Healthcare Moves: A Monthly Summary of Hires and Layoffs
Here is a selection of recent executive hires, promotions and layoffs occurring across the healthcare industry.
J&J’s venture arm backs CVRx in $93 million funding round
CVRx, which has struggled to get the FDA nod for an earlier generation device, will use the money to progress its pivotal clinical trial in the U.S. to treat patients with congestive heart failure using neuromodulation.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Maker of neuromodulator to treat heart failure, CVRx, raises $46M
Neuromodulation is gaining ground as a therapy for reducing pain, but no one has yet harnessed it within the cardiology arena, putting the company in a unique position if the Barostim gains FDA approval and commercial success.
Don’t let the IPOs fool you. Healthcare deal activity and funding were down in Q3
Womp womp. Though Q3 saw 13 healthcare industry IPOs–a five-quarter high, the past quarter also had the lowest financing amount for healthcare in the last five quarters, according to CB Insights. Funding declined 36 percent from Q2. Medical devices represented 33 percent of healthcare venture capital financing. Surprisingly, Series A and seed funding combined pulled […]
Some bright news at the end of very dark tunnel: VC firm raises an oversubscribed round for late-stage medtech companies
Just when it looks like it’s time for the device industry to karaoke some Alanis Morissette and find a new partner than venture capital, there is a little hope. Despite the 29 percent drop in venture capital funding to medical devices in the first half of 2013, Minneapolis VC firm SightLine Partners has closed a $107 million […]
Minnesota company raises $29.6 million for implantable hypertension technology
CVRx, a Minneapolis-based firm that has developed proprietary implantable technology for the treatment of high blood pressure and heart failure, has raised $29.6 million for advancing clinical trials of its Barostim Neo, as well as expanding commercial activities abroad. Johnson & Johnson Development Corp. and New Enterprise Associates, Inc. were the co-lead investors. According to […]
presented by
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Minnesota hypertension treatment firm names new chief commercial officer
Privately held CVRx that has created an implantable device to treat high blood pressure announced Monday that it has named Philippe Wanstok to the newly created position of chief commercial officer. Wanstok will oversee the worldwide commercialization of the neurostimulation product called the Barostim Neo, which bear the CE Mark and is currently available in […]